Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia
复制标题
DOI：
10.1056/nejmoa030513
复制
发表时间：
2003-10-09
影响因子：
158.5
通讯作者：
Holmes, H
中科院分区：
文献类型：
--
作者：
Hughes, TP;Kaeda, J;Holmes, H
背景：在一项随机试验中，1106例慢性期慢性粒细胞白血病（CML）患者被分配接受伊马替尼或干扰素α联合阿糖胞苷作为初始治疗。我们测量了BCR-ABL转录水平在本试验中的所有患者的血液中有一个完全的细胞遗传学relevance.METHODS：BCR-ABL转录水平进行了测量，通过定量实时聚合酶链反应测定。结果表示相对于中位水平的BCR-ABL转录在血液中的30例未经治疗的慢性粒细胞白血病在慢性phase.Results：在患者谁有一个完全的细胞遗传学缓解，BCR-ABL转录水平治疗12个月后下降了至少3个对数在伊马替尼组的57%和干扰素加阿糖胞苷组的24%（P=0.003）。基于伊马替尼组12个月时细胞遗传学完全缓解率为68%，干扰素+阿糖胞苷组为7%，估计所有接受伊马替尼治疗的患者中有39%，而所有接受干扰素+阿糖胞苷治疗的患者中只有2%的BCR-ABL转录水平降低至少3 log（P
BACKGROUND:In a randomized trial, 1106 patients with chronic myeloid leukemia (CML) in chronic phase were assigned to imatinib or interferon alfa plus cytarabine as initial therapy. We measured levels of BCR-ABL transcripts in the blood of all patients in this trial who had a complete cytogenetic remission.METHODS:Levels of BCR-ABL transcripts were measured by a quantitative real-time polymerase-chain-reaction assay. Results were expressed relative to the median level of BCR-ABL transcripts in the blood of 30 patients with untreated CML in chronic phase.RESULTS:In patients who had a complete cytogenetic remission, levels of BCR-ABL transcripts after 12 months of treatment had fallen by at least 3 log in 57 percent of those in the imatinib group and 24 percent of those in the group given interferon plus cytarabine (P=0.003). On the basis of the rates of complete cytogenetic remission of 68 percent in the imatinib group and 7 percent in the group given interferon plus cytarabine at 12 months, an estimated 39 percent of all patients treated with imatinib but only 2 percent of all those given interferon plus cytarabine had a reduction in BCR-ABL transcript levels of at least 3 log (P